Navigation Links
ViroPharma in Medical News

Vincent J. Milano to Succeed Michel de Rosen as President and Chief Executive Officer of ViroPharma

- Michel de Rosen to Continue as Chairman of the Board of Directors; Daniel B. Soland Promoted to Chief Operating Officer - EXTON, Pa., Feb. 26 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM ) announced today that, effective March 31, 2008, Vincent J. Milano will suc...

ViroPharma Announces Initiation Of Non-Toxigenic Clostridium Difficile Phase 1 Program

... EXTON, Pa., Aug. 6 /PRNewswire-FirstCall/ -- viropharma Incorporated (Nasdaq: VPHM ) today announced tha...nitis and perforation of the colon. About viropharma Incorporated viropharma Incorporated is a biopharmaceutical company dedica...

ViroPharma Announces Support by Advisory Committee of The Office of Generic Drugs Proposed Guidelines for Developing Generic Versions of Oral Vancomycin Hydorchloride

...TON, Pa., Aug. 4 /PRNewswire-FirstCall/ -- viropharma Incorporated (Nasdaq: VPHM ) today announced tha...BE rather than using comparative clinical trials. viropharma scientists and other leading experts voiced their ...onitis and perforation of the colon. About viropharma Incorporated ...

ViroPharma Incorporated Reports Second Quarter 2009 Financial Results

... EXTON, Pa., July 29 /PRNewswire-FirstCall/ -- viropharma Incorporated (Nasdaq: VPHM ) reported today its ... million. Looking ahead in 2009 viropharma is revising its guidance for the year 2009. The following guidance provided by viropharma are projections, based upon numerous assumptions, ...

ViroPharma to Release 2009 Second Quarter Financial Results on July 29, 2009

... EXTON, Pa., July 14 /PRNewswire-FirstCall/ -- viropharma Incorporated's (Nasdaq: VPHM ) second quarter fi...Time on the same day. During the conference call, viropharma management will discuss the 2009 second quarter an...all, please tell the operator you wish to join the viropharma investor conference call. About...

Changing Paradigms in Hereditary Angioedema: A Focus on Timely Diagnosis and New Therapies

... Changing Paradigms in Hereditary Angioedema: A Focus on Timely Diagnosis and New Therapies . This activity is supported by an educational grant from viropharma Incorporated. Faculty for this continuing medical education activity include the following experts in allergy and immunology: Allen P. Kaplan, MD...

Changing Paradigms in Hereditary Angioedema: Pathophysiology, Diagnosis and Treatment

...rived from a live symposium which took place on February 13, 2009 in Fort Lauderdale, Florida. This activity is supported by an educational grant from viropharma Incorporated and is accredited for physicians. Faculty reviewers include Michael M. Frank, MD from Duke University School of Medicine in Durham...

New Directions in Angioedema: A Focus on Etiologies and Clinical Approach

...ned to assist physicians and nurses in understanding the etiology and diagnosis of angioedema. This activity is supported by an educational grant from viropharma Incorporated. Timothy J. Craig, DO, Professor of Medicine and Pediatrics at the Pennsylvania State University College of Medicine in Hershey, P...

ViroPharma Announces Appointment of Frank Baldino, Jr., Ph.D. to Board of Directors

... EXTON, Pa., June 8 /PRNewswire-FirstCall/ -- viropharma Incorporated (Nasdaq: VPHM ) today announced the...rom his guidance and his experience. He brings to viropharma a wealth of experience in virtually any issue that...for NicOx, S.A., and Acusphere, Inc. About viropharma Incorporated ...

ViroPharma Announces Meeting of FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology on Bioequivalence Recommendations for Oral Vancomycin Hydrochloride Products

...tonitis and perforation of the colon. About viropharma Incorporated viropharma Incorporated is a biopharmaceutical company dedica...by physician specialists and in hospital settings. viropharma commercializes Vancocin(R), approved for oral admi...
ViroPharma in Medical Technology

Scientific Data Relating to Cinryze(TM) Presented at 6th Annual C1 Inhibitor Deficiency Workshop

...y and EXTON, Pa., May 26 /PRNewswire-FirstCall/ -- viropharma Incorporated (Nasdaq: VPHM ) today announced the...tacks in adults and adolescents. In February 2009, viropharma was granted priority review of a supplemental Biol...potential for subcutaneous infusion, among others, viropharma is demonstrating our commitment to meeting the nee...

ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance

... EXTON, Pa., March 18 /PRNewswire-FirstCall/ -- viropharma Incorporated (Nasdaq: VPHM ) today announced its... use of OGD's proposed new BE method for Vancocin, viropharma also believes that, even if the new method was val...tandard. Unless those products are reformulated, viropharma believes they should not possess "comparable disso...

Changing Paradigms in Hereditary Angioedema: A Focus on Prompt Diagnosis and New Therapies

...tivity, titled Changing Paradigms in Hereditary Angioedema: A Focus on Prompt Diagnosis and New Therapies, is supported by an educational grant from viropharma Incorporated and is accredited for physicians, nurses, and pharmacists. The faculty for these lectures comprises experts in immunology and HAE fr...

ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients

... EXTON, Pa., Feb. 13 /PRNewswire-FirstCall/ -- viropharma Incorporated (Nasdaq: VPHM ) today announced tha...w suppression and renal impairment. About viropharma Incorporated viropharma Incorporated is a biopharmaceutical company dedica...

FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE)

... EXTON, Pa., Feb. 3 /PRNewswire-FirstCall/ -- viropharma Incorporated (Nasdaq: VPHM ) today announced tha...ciation's website at: www.haea.org . About viropharma Incorporated viropharma Incorporated is a biopharmaceutical company dedica...

ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema

... - EXTON, Pa., Nov. 12 /PRNewswire-FirstCall/ -- viropharma Incorporated (Nasdaq: VPHM ) today announced the ...ation's website at: http://www.haea.org . About viropharma Incorporated viropharma Incorporated is a biopharmaceutical company dedica...

ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals

... - EXTON, Pa., Oct. 21 /PRNewswire-FirstCall/ -- viropharma Incorporated (Nasdaq: VPHM ) today announced it h...ers will receive $2.25 in cash, 0.042146 shares of viropharma common stock and one non- transferable contingent ...ev common stock that they own. The total number of viropharma shares to be issued as part of the merger consider...

Current Concepts in Clostridium difficile Infection: A Focus on Recurrent Disease

...is jointly sponsored by Robert Michael Educational Institute LLC and Postgraduate Institute for Medicine and is supported by an educational grant from viropharma Incorporated. Robert Michael Educational Institute LLC is a full-service medical education company dedicated to providing comprehensive medical educ...

ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients

...s - EXTON, Pa., May 29 /PRNewswire-FirstCall/ -- viropharma Incorporated (Nasdaq: VPHM ) today announced that...e marrow suppression and renal impairment. About viropharma Incorporated viropharma Incorporated is a biopharmaceutical company dedica...

ViroPharma Announces Discontinuation of HCV-796 Development

... EXTON, Pa., April 16 /PRNewswire-FirstCall/ -- viropharma Incorporated (Nasdaq: VPHM ) announced today that viropharma and Wyeth Pharmaceuticals, a division of Wyeth (NY...t standard of care. ViroPharma also announced that viropharma and Wyeth do not expect to continue to collaborate...
ViroPharma in Biological Technology

Clostridium difficile Infection: Strategic Approaches for Better Outcomes

...uing education lectures conveniently located at medical institutions across the United States. This activity is supported by an educational grant from viropharma Incorporated and is accredited for physicians, pharmacists, and registered nurses. Faculty for these lectures are leading experts in infectious d...

ViroPharma Receives Complete Response Letter for Cinryze(TM) Supplemental Biologics License Application for Acute Treatment of Hereditary Angioedema

... EXTON, Pa., June 4 /PRNewswire-FirstCall/ -- viropharma Incorporated (Nasdaq: VPHM ) today announced tha...Cinryze in the clinical studies. In addition, viropharma announced that FDA has approved the patient labeli...iation's website at: www.haea.org . About viropharma Incorporated ...

ViroPharma to Present at Two June Healthcare Conferences

... EXTON, Pa., June 2 /PRNewswire-FirstCall/ -- viropharma Incorporated (Nasdaq: VPHM ) today announced tha...ing held at the Grand Hyatt in New York City. viropharma also announced that William Roberts, vice presiden...of 14 days following the conferences. About viropharma Incorporated ...

ViroPharma Incorporated Honored by the National Organization for Rare Disorders

... EXTON, Pa., May 18 /PRNewswire-FirstCall/ -- viropharma Incorporated (Nasdaq: VPHM ) was honored with a ... "but what is even more gratifying for everyone at viropharma is making a difference in the lives of HAE patient...tacks in adults and adolescents. In February 2009, viropharma was granted priority review of a supplemental Biol...

ViroPharma Incorporated Reports First Quarter 2009 Financial Results

... EXTON, Pa., April 29 /PRNewswire-FirstCall/ -- viropharma Incorporated (Nasdaq: VPHM ) reported today its ...$9.2 million. Looking ahead in 2009 viropharma is reiterating its guidance for the year 2009 as a... to investors. The following guidance provided by viropharma are projections, based upon numerous assumptions, ...

ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009

... EXTON, Pa., April 22 /PRNewswire-FirstCall/ -- viropharma Incorporated's (Nasdaq: VPHM ) first quarter fin...Time on the same day. During the conference call, viropharma management will discuss the 2009 first quarter and...all, please tell the operator you wish to join the viropharma investor conference call. About...

ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes

... EXTON, Pa., March 24 /PRNewswire/ -- viropharma Incorporated (Nasdaq: VPHM ) announced it has re... As a result of the convertible note repurchase, viropharma expects that its fully diluted shares outstanding ...nancial statements for the first quarter of 2009. viropharma anticipates that the taxable gain arising from the...

ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results

... EXTON, Pa., Feb. 24 /PRNewswire-FirstCall/ -- viropharma Incorporated (Nasdaq: VPHM ) reported today its ...for maribavir, 2008 was a very successful year for viropharma -- from strong financial results to great executio... of $2.25 per share in cash and $0.50 per share in viropharma common stock, and contingent consideration (CVRs) ...

Clostridium difficile Infection: Current Challenges and Controversies

...and nurses titled Clostridium difficile Infection: Current Challenges and Controversies. This activity is supported by an educational grant from viropharma Incorporated. The information contained in this virtual lecture and podcast was originally presented as a live symposium during the 2008 ICAAC/...

ViroPharma to Present at Three November Healthcare Conferences

... EXTON, Pa., Nov. 6 /PRNewswire-FirstCall/ -- viropharma Incorporated (Nasdaq: VPHM ) today announced that...ence is being held at the New York Palace Hotel. viropharma also announced that Colin Broom, vice president, chief scientific officer of viropharma will present at the Lazard Capital Markets 5th Ann...
Other Tags
(Date:5/23/2015)... A live auction will be held to sell over 5,200 ... medical facilities around the United States. Various types of ... exam and much more. , The live auction will ... at 9:00am CDT each day. The equipment is at their ... IL 60160. Anyone can participate in the auction including ...
(Date:5/23/2015)... Viejo, CA (PRWEB) May 23, 2015 Add ... from Pixel Film Studios. , It's as simple as ... as utilizing the included tool for full effect. , ... filmed on high-dynamic range 5k sensors making this the ultimate ... The prismatic flares included in this package are movie files ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 The ... communication and capacity are intersecting to create new ... society, the opening speaker at WesternU's 34th annual ... Lieut. Gov. Gavin Newsom, a former San Francisco ... keynote speaker at the graduation ceremony for WesternU's ...
(Date:5/22/2015)... San Francisco, CA (PRWEB) May 22, 2015 ... is hosting two exciting events in June. They will ... First Professional Doctorate and a two-day class on Classical ... 1:30-2:30 p.m. June 3, Dr. Steve Given, the Dean ... he will discuss the new First Professional Doctorate program. ...
(Date:5/22/2015)... East Liverpool, OH (PRWEB) May 22, 2015 ... today announced that Kyle Johnson, the health system’s Chief ... pursue other interests. Johnson has served as the company ... announced Wesley West will be joining the health system ... operations on an interim basis, while the Board of ...
Breaking Medicine News(10 mins):Health News:Over 5,200 Lots of Medical Equipment Will Be Sold by Live Auction 2Health News:Developers at Pixel Film Studios Release ProFlare 5K Prism for Final Cut Pro X. 2Health News:Newsom to WesternU Grads: The Future is Inside You 2Health News:Newsom to WesternU Grads: The Future is Inside You 3Health News:ACTCM Announces Upcoming June Events 2Health News:River Valley Health Partners Announces CFO Transition, Appointment of Interim CFO 2
(Date:5/11/2015)... , May 11, 2015 Curemark LLC, a ... start of a new Phase III double blind, randomized, ... novel formulation, CM-AT, on all children ages 3-8 with ... FDA Phase III double blinded clinical trial for CM-AT ... levels of the digestive enzyme chymotrypsin. This new trial ...
(Date:5/5/2015)... Conn. , May 5, 2015, NXT-ID, Inc. ... authentication company focused on the growing mobile commerce market, reminds ... Company,s Chief Technology Officer, is presenting  at CARTES SECURE CONNEXIONS ... May 5-7, 2015. The three-day conference is ... David is speaking in is themed Global Fraud: Where ...
(Date:4/20/2015)... PASADENA, Calif. , April 20, 2015 ... San Gabriel Valley to implant a new miniaturized, wireless ... HF System is the first and only FDA-approved heart ... reduce hospital admissions when used by physicians to manage ... a sensor that is implanted in the pulmonary artery ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3
Other Contents